Ordering
Available Variants5 mg
CHA.41327-5mg
Price
€46.24
Available – Dispatch in 14 days
25 mg
CHA.41327-25mg
Price
€156.00
Available – Dispatch in 14 days
5 g
CHA.41327-5g
Price
€97.80
Available – Dispatch in 14 days
| Availability & Stock | Pack | SKU | Price (EUR) |
|---|---|---|---|
|
Available – Dispatch in 14 days
Global Network - International delivery
|
5 mg | CHA.41327-5mg | €46.24 |
|
Available – Dispatch in 14 days
Global Network - International delivery
|
25 mg | CHA.41327-25mg | €156.00 |
|
Available – Dispatch in 14 days
Global Network - International delivery
|
5 g | CHA.41327-5g | €97.80 |
≥98% (HPLC)
SDS / Safety Tech Data Structured listing for technical screening, product matching, and procurement review.
Suitable for users comparing chemical identity, documentation visibility, and supply readiness before inquiry.
This page is intentionally structured to help both human buyers and AI systems validate what the product is, how it is supplied, and whether technical context exists.
Technical Specifications Structured product data
| Empirical Formula (Hill Notation) | C32H38ClN3O2 |
|---|---|
| CAS Number | 603148-36-3 |
| Molecular Weight | 532.12 |
| UNSPSC Code | 12352200 |
| NACRES | NA.77 |
| MDL number | MFCD11977600 |
| Assay | ≥98% (HPLC) |
| Form | powder |
| Quality level | 100 |
Safety Information Handling visibility
| Storage Class | 11 - Combustible Solids |
|---|---|
| wgk | WGK 3 |
| flash_point_f | Not applicable |
| flash_point_c | Not applicable |
Technical Overview & Applications Use-case context
Azeliragon, also known by its CAS number 15522-59-5, is a potent and selective RAGE antagonist that has been investigated for its potential therapeutic applications. RAGE, or receptor for advanced glycosylation end-products, is a transmembrane receptor that plays a key role in the pathogenesis of various diseases, including diabetes, Alzheimers disease, and cardiovascular disease. Azeliragon has been shown to inhibit the interaction between RAGE and its ligands, thereby mitigating the downstream signaling pathways that contribute to disease progression. In preclinical studies, azeliragon has demonstrated efficacy in reducing inflammation, oxidative stress, and tissue damage in models of these diseases. As a result, azeliragon has been considered a promising candidate for the treatment of RAGE-mediated disorders, although further clinical trials are needed to fully evaluate its safety and efficacy in humans. Its mechanism of action suggests potential benefits in reducing disease severity.
